The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ELCC 2016 | Overcoming molecular mechanisms of resistance to therapies for non-small cell lung cancer

Name: Overcoming molecular mechanisms of resistance to therapies for non-small cell lung cancer
Uploaded: 2016-04-15T00:00:00.000Z
Duration: 1 min 7 s
Description: At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Enriqueta Felip, MD, PhD, from Vall d’Hebron Institute of Oncology, Barcelona, Spain, provides an overview of therapeutic approaches based on an increasing molecular level understanding of tumors to overcome acquired resistance in patients with non-small cell lung cancer.

Enriqueta Felip • 15 Apr 2016

ELCC 2016

Lung Cancer

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Enriqueta Felip, MD, PhD, from Vall d’Hebron Institute of Oncology, Barcelona, Spain, provides an overview of therapeutic approaches based on an increasing molecular level understanding of tumors to overcome acquired resistance in patients with non-small cell lung cancer.